Green Cross Corp Market Cap ($1.01 Billion)
Market Cap & Net Worth: Green Cross Corp (006280)
Green Cross Corp market cap. Green Cross Corp (KO:006280) has a market capitalization of $1.01 Billion (₩1.49 Trillion) as of November 3, 2026. Listed on the KO stock exchange, this Korea-based company holds position #8522 globally and #217 in its home market, demonstrating a -0.61% decrease in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying Green Cross Corp's stock price ₩130200.00 by its total outstanding shares 11413178 (11.41 Million). Also see 006280 cash flow metrics for how efficiently the company converts equity into cash flow.
Green Cross Corp Market Cap History (2015–2026)
Green Cross Corp market cap history from 2015 to 2026. Data shows change from $1.34 Billion to $1.01 Billion (-2.10% CAGR). Check 006280 live share price for real-time trading data and today's change.
Green Cross Corp Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how Green Cross Corp's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance. Explore Green Cross Corp (006280) equity growth momentum to track how rapidly the company is growing its equity base year over year.
Latest Price to Sales (P/S) Ratio
0.00x
Green Cross Corp's market cap is 0.00 times its annual revenue
Latest Price to Earnings (P/E) Ratio
N/A
P/E ratio not applicable due to negative or zero earnings
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| 2015 | $1.34 Billion | $1.05 Trillion | $94.97 Billion | 0.00x | 0.01x |
| 2016 | $1.16 Billion | $1.20 Trillion | $62.97 Billion | 0.00x | 0.02x |
| 2017 | $1.67 Billion | $1.29 Trillion | $53.25 Billion | 0.00x | 0.03x |
| 2018 | $1.02 Billion | $1.33 Trillion | $34.43 Billion | 0.00x | 0.03x |
| 2019 | $996.58 Million | $1.37 Trillion | -$3.64 Billion | 0.00x | N/A |
| 2020 | $3.07 Billion | $1.50 Trillion | $81.05 Billion | 0.00x | 0.04x |
| 2021 | $1.66 Billion | $1.54 Trillion | $123.21 Billion | 0.00x | 0.01x |
| 2022 | $1.00 Billion | $1.71 Trillion | $65.45 Billion | 0.00x | 0.02x |
| 2023 | $970.69 Million | $1.63 Trillion | -$26.63 Billion | 0.00x | N/A |
| 2024 | $1.39 Billion | $1.68 Trillion | -$26.28 Billion | 0.00x | N/A |
Competitor Companies of 006280 by Market Capitalization
Companies near Green Cross Corp in the global market cap rankings as of November 3, 2026. Also see how large is Green Cross Corp's balance sheet for a full breakdown of the balance sheet.
Key companies related to Green Cross Corp by market ranking:
- Takeda Pharmaceutical Co Ltd ADR (NYSE:TAK): Ranked #511 globally with a market cap of $52.60 Billion USD.
- GALDERMA GROUP AG (NYSE:GALDY): Ranked #535 globally with a market cap of $50.42 Billion USD.
- Jiangsu Hengrui Medicine Co Ltd (SHG:600276): Ranked #593 globally with a market cap of $45.23 Billion USD ( CN¥309.13 Billion CNY).
- Takeda Pharmaceutical Company Limited (F:TKDA): Ranked #619 globally with a market cap of $43.60 Billion USD ( €37.29 Billion EUR).
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #511 | Takeda Pharmaceutical Co Ltd ADR | NYSE:TAK | $52.60 Billion | $16.65 |
| #535 | GALDERMA GROUP AG | NYSE:GALDY | $50.42 Billion | $46.59 |
| #593 | Jiangsu Hengrui Medicine Co Ltd | SHG:600276 | $45.23 Billion | CN¥48.46 |
| #619 | Takeda Pharmaceutical Company Limited | F:TKDA | $43.60 Billion | €18.30 |
Market Capitalization of Green Cross Corp (2015–2026)
Market capitalization of Green Cross Corp from 2015 to today. Between 2015 and today, Green Cross Corp's market cap moved from $1.34 Billion to $ 1.01 Billion, with a yearly change of -2.10%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2026 | ₩1.01 Billion | -18.11% |
| 2025 | ₩1.23 Billion | -11.42% |
| 2024 | ₩1.39 Billion | +43.03% |
| 2023 | ₩970.69 Million | -3.09% |
| 2022 | ₩1.00 Billion | -39.72% |
| 2021 | ₩1.66 Billion | -45.82% |
| 2020 | ₩3.07 Billion | +207.72% |
| 2019 | ₩996.58 Million | -1.82% |
| 2018 | ₩1.02 Billion | -39.37% |
| 2017 | ₩1.67 Billion | +44.76% |
| 2016 | ₩1.16 Billion | -13.52% |
| 2015 | ₩1.34 Billion | -- |
End of Day Market Cap According to Different Sources
On Nov 2nd, 2026 the market cap of Green Cross Corp was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $1.01 Billion USD |
| MoneyControl | $1.01 Billion USD |
| MarketWatch | $1.01 Billion USD |
| marketcap.company | $1.01 Billion USD |
| Reuters | $1.01 Billion USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.
About Green Cross Corp
GC Biopharma Corp., a biopharmaceutical company, develops and sells pharmaceutical drugs in South Korea and internationally. It provides over-the-counter drugs, such as Acustop Cataplasma for Analgesic and anti-inflammatory effect; Kenhancer plaster for anti-inflammatory; and Zenol Cool Type and Zenol Mild Hot Type drugs to treat anti-inflammatory and pain relief. The company also offers Albumin-… Read more